AU2018313765A1 - Compositions and methods for decolonizing antibotic-resistant bacteria in the gut - Google Patents

Compositions and methods for decolonizing antibotic-resistant bacteria in the gut Download PDF

Info

Publication number
AU2018313765A1
AU2018313765A1 AU2018313765A AU2018313765A AU2018313765A1 AU 2018313765 A1 AU2018313765 A1 AU 2018313765A1 AU 2018313765 A AU2018313765 A AU 2018313765A AU 2018313765 A AU2018313765 A AU 2018313765A AU 2018313765 A1 AU2018313765 A1 AU 2018313765A1
Authority
AU
Australia
Prior art keywords
bacteria
bacterial
pharmaceutical composition
firmicutes
clostridiales
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018313765A
Other languages
English (en)
Inventor
Kevin Roelofs
Marina SANTIAGO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Finch Therapeutics Inc
Original Assignee
Finch Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Finch Therapeutics Inc filed Critical Finch Therapeutics Inc
Publication of AU2018313765A1 publication Critical patent/AU2018313765A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2018313765A 2017-08-07 2018-08-07 Compositions and methods for decolonizing antibotic-resistant bacteria in the gut Abandoned AU2018313765A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762542033P 2017-08-07 2017-08-07
US62/542,033 2017-08-07
PCT/US2018/045592 WO2019032572A1 (en) 2017-08-07 2018-08-07 COMPOSITIONS AND METHODS FOR DECOLONIZING ANTIBIOTIC-RESISTANT BACTERIA IN INTESTINES

Publications (1)

Publication Number Publication Date
AU2018313765A1 true AU2018313765A1 (en) 2020-02-27

Family

ID=65272652

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018313765A Abandoned AU2018313765A1 (en) 2017-08-07 2018-08-07 Compositions and methods for decolonizing antibotic-resistant bacteria in the gut

Country Status (8)

Country Link
US (2) US20200093870A1 (cg-RX-API-DMAC7.html)
EP (1) EP3665181A4 (cg-RX-API-DMAC7.html)
JP (1) JP2020530493A (cg-RX-API-DMAC7.html)
KR (1) KR20200037851A (cg-RX-API-DMAC7.html)
CN (1) CN111328331A (cg-RX-API-DMAC7.html)
AU (1) AU2018313765A1 (cg-RX-API-DMAC7.html)
CA (1) CA3072029A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019032572A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性t細胞の増殖または集積を誘導する作用を有する組成物
CA2892588A1 (en) 2011-12-01 2013-06-06 School Corporation, Azabu Veterinary Medicine Educational Institution Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
KR20200038506A (ko) 2017-08-07 2020-04-13 핀치 테라퓨틱스, 인코포레이티드 건강한 장 장벽을 유지 및 회복시키기 위한 조성물 및 방법
WO2019079629A1 (en) * 2017-10-18 2019-04-25 Ascus Biosciences, Inc. IMPROVING POULTRY PRODUCTION BY ADMINISTERING A SYNTHETIC BIO-ASSEMBLY OF MICROBES OR PURIFIED STEM THEREFOR
AU2019253714A1 (en) 2018-04-10 2020-11-26 Siolta Therapeutics, Inc. Microbial consortia
MX2021007599A (es) * 2018-12-19 2021-10-13 Healthy Cow Corp Composiciones probióticas listas para utilizar y usos de las mismas.
WO2021016081A1 (en) 2019-07-19 2021-01-28 Finch Therapeutics Holdings Llc. Methods and products for treatment of gastrointestinal disorders
CN114728026A (zh) * 2019-08-28 2022-07-08 未知君有限责任公司 包含细菌物种的组合物及与其相关的方法
AU2020354581A1 (en) 2019-09-24 2022-03-03 Prolacta Bioscience, Inc. Compositions and methods for treatment of inflammatory and immune diseases
JP7624449B2 (ja) 2019-10-07 2025-01-30 シオルタ・セラピューティクス,インコーポレイテッド 治療用医薬組成物
CA3158132A1 (en) * 2019-10-18 2021-04-22 Finch Therapeutics Holdings Llc Compositions and methods for delivering a bacterial metabolite to a subject
GB201915144D0 (en) * 2019-10-18 2019-12-04 Multigerm Uk Entpr Ltd Method of promoting SCFA production by gut microbiota
EP3838281A1 (en) * 2019-12-20 2021-06-23 4D Pharma Research Limited Compositions comprising bacterial strains
WO2021231804A2 (en) * 2020-05-13 2021-11-18 President And Fellows Of Harvard College Methods and compositions for suppressing inflammation induced by gut microbes
GB202007452D0 (en) 2020-05-19 2020-07-01 Microbiotica Ltd Threrapeutic bacterial composition
CA3188645A1 (en) 2020-08-14 2022-02-17 Prolacta Bioscience, Inc. Human milk oligosaccharide compositions for use with bacteriotherapies
WO2022050082A1 (ja) * 2020-09-01 2022-03-10 国立大学法人東北大学 乳汁中のIgA抗体含有量の増加剤
JP7852863B2 (ja) * 2020-09-30 2026-04-28 国立研究開発法人国立がん研究センター ルミノコッカッセ腸内菌投与による免疫チェックポイント阻害薬の抗腫瘍効果の増強
AU2021388169A1 (en) * 2020-11-25 2023-07-13 Seres Therapeutics, Inc. Designed bacterial compositions for treating graft-versus-host-disease
US20230149483A1 (en) * 2021-11-12 2023-05-18 Iowa State University Research Foundation, Inc. Short-chain fatty acid use to mitigate antimicrobial resistance and virulence gene transfer in the gut
JPWO2023100989A1 (cg-RX-API-DMAC7.html) * 2021-12-02 2023-06-08
KR102780901B1 (ko) * 2022-11-09 2025-03-17 주식회사 굿바이옴텍 베타-락탐계 항생제 내성 유전자 blaCTX-M-229 및 퀴놀론계 항생제 내성 유전자 qnrS를 갖는 신규한 다제내성 대장균 균주 및 이의 용도
CN116747227B (zh) * 2023-08-12 2025-07-25 杭州市第一人民医院 泊马度胺在制备抗细菌感染药物中的应用
AU2024370585A1 (en) 2023-11-05 2026-06-18 Human Biome S.A. Functional compositions and methods of use thereof in eradication and/or decolonization of antibiotic-resistant bacteria and restoration of healthy microbiota
WO2025093780A1 (en) * 2023-11-05 2025-05-08 Human Biome Institute S.A. The concept of drugs made with the gut microbiota and its components and the method of their administration to obtain effective therapeutic effects

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727061B2 (en) * 1997-02-20 2004-04-27 Cabtec, Inc. Methods for identifying species or Shigella and E. coli using operon sequence analysis
EP1238071B1 (en) * 1999-11-29 2008-04-23 Avi Biopharma, Inc. Uncharged antisense oligonucleotides targeted to bacterial 16s and 23s rrnas and their uses
BR112013022927A2 (pt) * 2011-03-09 2016-12-06 Univ Minnesota composição, métodos para substituir ou suplementar ou modificar uma microbiota do cólon de um sujeito, e para tratar um sujeito, e, uso de uma composição
CA2892588A1 (en) * 2011-12-01 2013-06-06 School Corporation, Azabu Veterinary Medicine Educational Institution Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
US8921335B2 (en) * 2012-01-31 2014-12-30 The Regents Of The University Of California Oral delivery of nucleic acid-based gene interfering agents by Salmonella
JP2016519664A (ja) * 2013-03-15 2016-07-07 セレス セラピューティクス インコーポレイテッド ネットワークを基にした微生物組成物及び方法
KR102099503B1 (ko) * 2013-06-05 2020-04-09 리바이오틱스, 인코퍼레이티드 미생물상 복원 요법(mrt) 조성물
MA41020A (fr) * 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
GB201519088D0 (en) * 2015-10-28 2015-12-09 Metabogen Ab The use of bacteria formulations
KR20200038506A (ko) * 2017-08-07 2020-04-13 핀치 테라퓨틱스, 인코포레이티드 건강한 장 장벽을 유지 및 회복시키기 위한 조성물 및 방법

Also Published As

Publication number Publication date
JP2020530493A (ja) 2020-10-22
EP3665181A4 (en) 2021-06-09
WO2019032572A1 (en) 2019-02-14
EP3665181A1 (en) 2020-06-17
CN111328331A (zh) 2020-06-23
US20240307460A1 (en) 2024-09-19
US20200093870A1 (en) 2020-03-26
CA3072029A1 (en) 2019-02-14
KR20200037851A (ko) 2020-04-09

Similar Documents

Publication Publication Date Title
US20240307460A1 (en) Compositions and methods for decolonizing antibiotic-resistant bacteria in the gut
US20240033305A1 (en) Compositions and methods for maintaining and restoring a healthy gut barrier
US12350298B2 (en) Microbiome related immunotherapies
US20220257670A1 (en) Methods and products for treatment of gastrointestinal disorders
CA3147629A1 (en) Methods and products for treatment of gastrointestinal disorders
US20240263251A1 (en) Compositions and methods for providing secondary bile acids to a subject
WO2019032575A1 (en) TREATMENT OF LIVER DISEASE BY MODULATION OF MICROBIOMA
US20240226187A9 (en) Compositions and Methods for Delivering a Bacterial Metabolite to a Subject
HK40044298A (en) Microbiome related immunotherapies

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application